Racial Disparities Seen in Trials Supporting FDA Approvals for Multiple Myeloma
Black and Hispanic patients appear to be underrepresented in global clinical trials supporting FDA approval of multiple myeloma drugs.
Black and Hispanic patients appear to be underrepresented in global clinical trials supporting FDA approval of multiple myeloma drugs.
Researchers sought to determine whether a reinduction therapy approach using mitoxantrone with clofarabine would be safe and effective for pediatric patients with leukemia.
Initiation of revaccination appears to be delayed for a significant portion of pediatric patients following allo-HSCT.
Real-world data confirmed the efficacy and safety profiles of tisagenlecleucel in patients with relapsed/refractory ALL younger than 3 years old.
Survival for adolescent and young adult leukemia survivors remained below the general population at up to 30 years of follow-up.
The risk of dying from a subsequent primary cancer remained significantly elevated for 20 years or more for some patients.
Younger patients with cancer are “a high-risk population for poor outcomes from COVID-19,” according to researchers.
The addition of daratumumab resulted in a 41% reduction in the risk of disease progression or death.
Adding elotuzumab to lenalidomide and dexamethasone did not improve any efficacy outcomes.
Researchers sought to determine whether there were long-term benefits for patients with hematologic malignancies treated with allo-HSCT and omidubicel.